GSK plc (GSK, GSK.L) said that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for GSK5764227, its ...

GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.

The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for GSK5764227, GSK’227, ...

The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...

(Alliance News) - GSK PLC on Tuesday said the US Food & Drug Administration has granted a breakthrough therapy designation to its treatment for a form of bone cancer.

GSK plc announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) Designation for GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate (ADC) being evaluated ...

The European stock markets closed mostly higher in Tuesday trading as The Stoxx Europe gained 0.34%, Germany's DAX rose 0.66%, France's CAC increased 0.59%, the Swiss Market Index climbed 1.19%, while ...

designation to its investigational B7-H3-targeted antibody-drug conjugate (ADC), GSK5764227 (GSK’227), for the treatment of relapsed extensive-stage small-cell lung cancer (ES-SCLC). The PRIME ...

London: GSK plc has announced that the US Food and Drug Administration (USFDA) has granted Breakthrough Therapy Designation ...